TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31086947
Drug: Escherichia coli-produced
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli-produced bivalent HPV-16/18 vaccine
Study: 25618966
Drug: Dendritic cells
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cells (DCs) plus ginseng polysaccharides (GPS) administered thoracoscopically, once a week, 4 times for 30 days.
Study: 20453655
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg bolus injection)
Study: 16652085
Drug: Oral prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral prednisone for 2 weeks followed by intranasal budesonide for 12 weeks (Group A, n = 63)
Study: 16652085
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid treatment (Group B, n = 21)
Study: 12651643
Drug: Liberalized fasting
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberalized fasting (Group L): formula fasted for 4-6 hours before surgery
Study: 12651643
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L and T)
Study: 10092561
Drug: Regular weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular weekly aerobic training programme, three times a week for 12 months
Study: 971031
Drug: Methylphenidate/thioridazine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate/thioridazine combination
Study: 30885839
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (Group A)
Study: 30885839
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (Group C)
Study: 26964161
Drug: Fire needle
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fire needle treatment
Study: 19519910
Drug: Enteral Nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral Nutrition combined with Parenteral Nutrition (EN + PN)
Study: 15124680
Drug: Rituximab combined
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combined with chemotherapy
Study: 11269475
Drug: Individualized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized heparin dose calculated by an in vitro heparin dose‐response test (group HC)
Study: 11269475
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of heparin (300 IU/kg; group C)
Study: 9886723
Drug: Candoxatril (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatril (100 mg twice daily)
Study: 8290176
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (0.625 mg) (N = 28)
Study: 3569737
Drug: Omeprazole 10
Normalized name: omeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 10 mg/d (Om10)
Study: 3569737
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg/d (Om20)
Study: 30032884
Drug: Nebulised midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulised midazolam 0.2 mg kg‐1 (Group M)
Study: 30032884
Drug: Nebulised dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised dexmedetomidine 2 μg kg‐1 (Group D)
Study: 30032884
Drug: Nebulised ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised ketamine 2 mg kg‐1 (Group K)
Study: 20360183
Drug: Topical NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical NSAID
Study: 20360183
Drug: Oral NSAID
Normalized name: Ansaid Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral NSAID
Study: 8978585
Drug: ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 8 mg i.v. plus dexamethasone 20 mg i.v.
Study: 8978585
Drug: metoclopramide 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide 60 mg i.v. plus dexamethasone 20 mg i.v.
Study: 25632615
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (400 microg, two hours prior to MVA)
Study: 25632615
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 microg, two hours prior to MVA)
Study: 25632615
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Sublingual and Oral)
Study: 21277628
Drug: 20 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg ZEA/kg bw for 48 days
Study: 21277628
Drug: 40 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 μg ZEA/kg bw for 48 days
Study: 19217817
Drug: Strength training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strength training (twice weekly for 15 weeks followed by 24 weeks of unsupervised training)
Study: 14693613
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% 200 mg/40 mL infiltrated at the wound site and continuous infusion of ropivacaine 0.2% at 5 mL/h for 55 hours
Study: 14693613
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion at the same rate as the R group
Study: 22429066
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg/day continued
Study: 22429066
Drug: Milnacipran 100
Normalized name: milnacipran 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milnacipran 100 mg/day discontinued
Study: 19804497
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (group A)
Study: 18477073
Drug: Pre-operative oral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative oral carbohydrate drink (400 ml, 2 hours before surgery)
Study: 18477073
Drug: Pre-operative oral
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative oral carbohydrate drink
Study: 2180659
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group using an algorithm for adjustment of insulin dosage based on daily prebreakfast capillary blood glucose measurements
Study: 28762645
Drug: AHA-Ret Overnight
Approvals — FDA: no, EMA: no, PMDA: no
Description: AHA-Ret Overnight Cream (double-conjugate retinoid cream)
Study: 25884390
Drug: DHEA 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 75 mg once a day
Study: 21988544
Drug: Problem-Solving Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-Solving Therapy
Study: 17280527
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) replacement therapy, initially 2 microg/kg body weight/d, increased to a maximum of 12 microg/kg/d over 2 years.
Study: 17280527
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) replacement therapy in men.
Study: 17280527
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in men.
Study: 17280527
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) replacement therapy in women.
Study: 17280527
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in women.
Study: 17280527
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH) replacement therapy.
Study: 11575340
Drug: Propofol 1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1‐3 mg kg(‐1) h(‐1)
Study: 9650878
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDGF-BB and IGF-1 pre-treated dentine surface (group 4)
Study: 9650878
Drug: TTC conditioned
Approvals — FDA: no, EMA: no, PMDA: no
Description: TTC conditioned dentine surfaces treated with combination of PDGF-BB and IGF-1 (group 8)
Study: 2649987
Drug: Cisplatin, etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, etoposide, and ifosfamide combination
Study: 2649987
Drug: Ifosfamide in
Normalized name: ifosfamide Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide in first-line treatment
Study: 339283
Drug: 15(S)15-methyl prostaglandin
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(S)15-methyl prostaglandin F2alpha administered as a single intramuscular injection (0.6 mg)
Study: 339283
Drug: 15(S)15-methyl prostaglandin
Normalized name: 15(S)-15-Methyl Prostaglandin F2α
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(S)15-methyl prostaglandin F2alpha administered as vaginal suppositories (1.0 or 1.5 mg per suppository)
Study: 339283
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection (Group I)
Study: 339283
Drug: Vaginal suppositories
Normalized name: Miconazole Nitrate Vaginal Suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal suppositories (Group II)
Study: 30024027
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point acupressure (APA) treatment along with sleep hygiene practices
Study: 27067882
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS (5-Hz, 10 daily sessions)
Study: 25391168
Drug: Probiotics (Infloran:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Infloran: Lactobacillus acidophilus 1 x 10(9) and Bifidobacterium bifidum 1 x 10(9) organisms) at a dose of 125 mg/kg/dose twice a day for 6 weeks or until discharge
Study: 21925682
Drug: Amitifadine 25
Normalized name: Amitifadine
DrugBank: Amitifadine (DB05964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitifadine 25 mg BID for 2 weeks, then 50 mg BID for 4 weeks
Study: 17507743
Drug: Carbohydrate loading
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate loading (CHOL; 8.4 g x kg(‐1) x d(‐1) carbohydrate)
Study: 17507743
Drug: Normal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal diet (NORM; 5.2 g x kg(‐1) x d(‐1) carbohydrate)
Study: 17507743
Drug: Carbohydrate loading
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate loading (CHOL) in midluteal (ML) phase
Study: 17507743
Drug: Normal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal diet (NORM) in midluteal (ML) phase
Study: 16268966
Drug: Melatonin 3
Normalized name: melatonin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 3 mg nocte
Study: 8983335
Drug: Metyrapone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metyrapone (24 h treatment)
Study: 8983335
Drug: Hydrocortisone (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (24 h treatment)
Study: 8983335
Drug: Placebo (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (24 h treatment)
Study: 6295985
Drug: Intraperitoneal antiserum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal antiserum and multiagent chemotherapy
Study: 22305828
Drug: Prasugrel-based antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel-based antiplatelet therapy for 12 months
Study: 22305828
Drug: Prasugrel-based antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel-based antiplatelet therapy for 1 month (in stable patients with BMS)
Study: 20226286
Drug: Ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg/month
Study: 14571283
Drug: Formulation A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation A: 2 x 500 mg paracetamol tablets (Laboratorios Belmac S.A.)
Study: 14571283
Drug: Formulation B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B: 1 x 1,000 mg paracetamol powder sachets (Laboratorios Belmac, S.A.)
Study: 14571283
Drug: Formulation C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C: 2 x 500 mg paracetamol film-coated tablets (Panadol, SmithKline Beecham)
Study: 14571283
Drug: Formulation D:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation D: 2 x 500 mg paracetamol tablets (Tylenol, McNeil)
Study: 14571283
Drug: Formulation E:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation E: 1 x 1,000 mg effervescent paracetamol tablets (Efferalgan, UPSA)
Study: 6347752
Drug: Verapamil 200
Normalized name: verapamil 200 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 200 mg b.i.d.
Study: 31596819
Drug: NLP-based models
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP-based models (Model 7, combination of Models 1 and 4)
Study: 28845898
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75-mg capsule before RYGB
Study: 28845898
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER 75-mg capsule after RYGB
Study: 15611894
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure (nCPAP) therapy
Study: 11586699
Drug: Zolpidem (ivadal)
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem (ivadal) 10 mg once daily before sleep for 2 weeks
Study: 1927064
Drug: Misoprostol 200
Normalized name: MISOPROSTOL 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 200 micrograms twice daily after meals
Study: 31860407
Drug: Intravenous glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glucocorticoids (IVGCs)
Study: 31860407
Drug: Oral glucocorticoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticoids (OGCs)
Study: 24989138
Drug: IV tedizolid
Normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tedizolid phosphate 100-400 mg
Study: 24989138
Drug: IV tedizolid
Normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tedizolid phosphate 200 mg once/day for 7 days
Study: 24989138
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of tedizolid phosphate 200 mg
Study: 24989138
Drug: IV tedizolid
Normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tedizolid phosphate 200 mg
Study: 20113145
Drug: Resilient appliance
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resilient appliance therapy
Study: 17976724
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab (0.5 mg) administered over a 2-year period
Study: 17976724
Drug: First-eye model
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-eye model of ranibizumab treatment
Study: 17976724
Drug: Combined model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined model of ranibizumab treatment
Study: 15990632
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy density feeds (oil added; caloric density = 35 kcal/100 g)
Study: 15990632
Drug: Low energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low energy density feeds (without oil; caloric density = 20 kcal/100 g)
Study: 10097838
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (10 sessions)
Study: 10097838
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy (10 sessions)
Study: 8835624
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (10-15 mg i.v.)
Study: 1596811
Drug: Homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Homeopathic treatment (thuya 30 CH, antimonium crudum 7 CH, nitricum acidum 7 CH)
Study: 22309265
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg iptakalim
Study: 22309265
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg iptakalim
Study: 22309265
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iptakalim
Study: 22309265
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg iptakalim (women)
Study: 22309265
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg iptakalim (women)
Study: 22309265
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg iptakalim (men)
Study: 22309265
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg iptakalim (fasting and nonfasting)
Study: 22309265
Drug: 5 mg,
Normalized name: Winrevair 45 MG, 2 Vial Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg, 10 mg, 20 mg iptakalim
Study: 17822876
Drug: Topical tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tacrolimus treatment
Study: 8740602
Drug: Cognitive self-hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive self-hypnosis (CSH) treatment
Study: 3481557
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tumor markers (carcinoembryonic antigen, ferritin, cancer antigen 125, tissue polypeptide antigen)
Study: 28914592
Drug: 0.2% HA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% HA gel
Study: 25468576
Drug: Caudal 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.25% levobupivacaine (Group L(0.25))
Study: 25468576
Drug: Caudal 0.20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.20% levobupivacaine (Group L(0.20))
Study: 25468576
Drug: Caudal 0.20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal 0.20% levobupivacaine plus 2 μg/kg dexmedetomidine (Group LD)
Study: 22289528
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of celecoxib and FOLFOX4 regimen (folinic acid‐fluorouracil‐oxaliplatin)
Study: 16638737
Drug: CS‐706 (2‐
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS‐706 (2‐ to 800‐mg doses daily, up to 14 days)
Study: 15580062
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml meal rich in fat
Study: 15580062
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml meal rich in carbohydrate
Study: 15580062
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml meal rich in protein
Study: 11298548
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine 250 mg daily (n = 30)
Study: 11298548
Drug: Placebo (moisturizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (moisturizing ointment) (n = 30)
Study: 11233189
Drug: Pacemaker (DDD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pacemaker (DDD) treatment
Study: 4817683
Drug: Mobilization headed
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization headed by a physician with written and oral instructions
Study: 24515943
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri 10^8 organisms once daily for 5 days
Study: 20976769
Drug: B-vitamins (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamins (daily folic acid 2 mg, vitamin B6 25 mg, vitamin B12 0.5 mg)
Study: 15722810
Drug: Multidisciplinary rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary rehabilitation (rheumatologist and physical therapist intake and discharge, 18 group supervised exercise therapy sessions, 2 group pain and stress management lectures, 1 group education lecture, 1 group dietary lecture, and 2 massage therapy sessions)
Study: 341689
Drug: Pyrogastrone (carbenoxolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrogastrone (carbenoxolone sodium with alginate antacid) for 8 weeks
Study: 341689
Drug: Control (alginate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (alginate antacid alone, Gaviscon‐like)
Study: 31981106
Drug: Netarsudil 0.02%/latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netarsudil 0.02%/latanoprost 0.005% fixed combination QD for 3 months
Study: 23071195
Drug: Historical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical treatment group with standard, in-person LSVT LOUD
Study: 18713796
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray treatment with Streptococcus sanguinis
Study: 18713796
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray treatment with Lactobacillus rhamnosus
Study: 9819038
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) continuous infusion
Study: 9819038
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) with heparin
Study: 9819038
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) with low‐molecular‐weight heparin (LMWH, enoxaparin)
Study: 9819038
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) with saline solution
Study: 9819038
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) continuous infusion systems
Study: 7806134
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogens (0.625 mg daily for 21 days) administered at 8 p.m.